DDInter478 DDInter1147
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296]
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Daratumumab may lead to a major life threatening interaction when taken with Cladribine
Daratumumab may lead to a major life threatening interaction when taken with Rotavirus vaccine